Compare · Head-to-head
Elamipretide vs MOTS-c.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Elamipretide, then use the table to confirm fit.
Elamipretide is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Elamipretide
Clinical-stage mitochondria-targeting peptide binding cardiolipin. Not a typical consumer RUO product.
01 · At a glance
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Primary fit | longevity & anti-aging research where you want a clear starting point | fat loss & metabolism and longevity & anti-aging comparisons |
| Evidence | Tier B | Tier C |
| Risk | medium | high |
| Experience level | advanced | advanced |
| Budget tier | premium | premium |
| Administration route | subcutaneous, intravenous | subcutaneous |
02 · Use case & timing
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Goal fit | Longevity & Anti-Aging | Fat Loss & Metabolism, Longevity & Anti-Aging |
| What users compare it for | Mitochondrial function improvement in disease contexts (clinical-stage). | Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice. |
| Onset timeline | Trial endpoints measured over months in disease-specific contexts. | Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Adverse effects | Injection site reactions common in some trial summaries; long-term safety depends on indication. | FDA: no identified human exposure data; significant immunogenicity/characterization risks. |
| Contraindications | Clinical trial context; not consumer self-administration. | No human data. |
| Interaction notes | Unknown in consumer context. | Unknown. |
| Regulatory status | Investigational | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Typical cycle cost | €371.52 | €33.02 |
| Estimated monthly cost | €371.52 | €33.02 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Elamipretide | MOTS-c |
|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.